华夏时报记者 郭怡琳 于娜 北京报道 一年两赴港交所，AI中医医疗服务商再冲IPO。 2025年7月29日，问止中医科技WenZhiTCM Inc.（下称"问止中医"）向港交所递交招股书，海通国际成 为独家保荐人。据悉，这是继今年1月9日首次递表，7月9日失效后的第二次冲击。这家成立仅七年的公 司凭借"中医+AI"模式，市场份额连续两年稳居行业榜首。 天眼查显示，问止中医成立于2018年，其创始人崔祥瑞有着鲜明的跨界背景，中山大学生命科学本科、 斯坦福大学MBA，兼具医疗投资经验。公司以线上互联网医院、线下中医诊所、中医智能产品为三大 板块主营业务，囊括中医生活产品（多种养生产品、在线录播课程及书籍）和"中医大脑"订阅服务。 一位不愿具名的中医领域二级市场分析师接受《华夏时报》记者采访时表示，"目前AI医疗风口仍在， 但中医与AI结合仍是难点。中医现代化探索若想避免沦为资本泡沫，需回归医疗本质，以疗效跨越质 疑，以口碑定义价值。近年来中医利好政策频发，中医概念企业发展乘风而行。" 此外，知名财税审计专家刘志耕表示，"上市可直接为企业提供多重支持，尤其对处于扩张期的企业至 关重要。资本市场认可为企业带来的品牌溢 ...

Group 1 - JingTai Technology (2228.HK) announced a collaboration with DoveTree, with a total order value of approximately HKD 47 billion, and has received an initial payment of about HKD 4 billion (USD 51 million) [1] - The collaboration will utilize JingTai's AI+robotics-based end-to-end drug discovery platform to identify and develop small molecule and antibody candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders [1] - This partnership sets a new record for order size in the AI+robotics drug development sector, with potential payments amounting to 159 times JingTai's projected revenue for 2024 [1] Group 2 - The Hong Kong Stock Connect Medical ETF (520510) will be launched on August 7, tracking an index with over 20% exposure to AI medical concepts [2] - The Hang Seng Medical ETF (159892) focuses on innovative drugs and includes holdings in companies such as Alibaba Health, JD Health, and JingTai Technology [3]

Core Viewpoint - The Hong Kong Stock Connect Medical ETF (trading code: 520510) is set to be listed on the Shanghai Stock Exchange on August 7, 2025, providing investors with a convenient tool to access the Hong Kong medical sector [1] Group 1: ETF Details - The ETF supports T+0 trading, filling a gap in the Hong Kong Stock Connect medical sector [1] - It tracks the Hong Kong Stock Connect Medical Theme Index (932069.CSI), which covers three major sub-sectors within the medical industry [1] Group 2: Index Composition - The ETF has over 30% weight in CXO holdings, leading among all market indices [1] - AI medical holdings account for over 20%, positioning the ETF to benefit from trends such as anti-involution, innovative drug exports, and the AI technology revolution [1]

Summary of the Conference Call for Yipinhong Company Overview - Yipinhong focuses on pediatric and chronic disease medications, with a strong emphasis on research and development. The company has over 20 years of experience in the pharmaceutical industry, showcasing robust capabilities in production, research, and sales channels [5][20]. Key Product: AR882 - AR882 is a novel gout treatment drug that demonstrates exceptional safety and efficacy, particularly in dissolving gout stones, positioning it as a potential best-in-class medication [2][6]. - The drug is currently undergoing global multi-center clinical trials, with interim data from overseas Phase III trials expected by the end of September 2023 [2][19]. - AR882 shows a significant uric acid reduction rate of 53%, outperforming allopurinol (35%) and febuxostat (30%) [2][15]. - Imaging data indicates that AR882 effectively dissolves both large and small gout stones [2][15]. - In a high-dose group presented at the European Rheumatology Annual Meeting, AR882 rapidly reduced blood uric acid levels to 4 mg/dL and maintained low levels over a year and a half, achieving a target rate of nearly 80% for levels below 6 mg/dL and 50% for levels below 4 mg/dL [16][17]. Market Potential - There are approximately 200 million patients with hyperuricemia in China, with about 20 million suffering from gout. Traditional uric acid-lowering medications have limitations, creating a significant market opportunity for AR882 [2][7][8]. - The global market for gout medications is projected to grow, with a notable increase in demand for new, effective treatments due to the limitations of existing therapies [13]. Clinical Trial Progress - The enrollment for the overseas Phase III trial is nearing completion, while the domestic Phase III trial aims to enroll over 600 patients, with more than 300 already enrolled [3][4][19]. - The company has a strong pipeline, with expectations to complete global Phase III trials by mid-2026 [4][19]. Safety Profile - AR882 has shown good safety in long-term treatment, with no liver or kidney toxicity events reported during a year and a half of observation. Most adverse reactions were mild to moderate [18][19]. Financial and Strategic Outlook - Yipinhong has launched a new equity incentive plan with performance targets, including a net profit growth rate of no less than 32%, reflecting strong confidence in future growth [3][4][21]. - The company is also exploring AI healthcare and molecular glue technologies, which are expected to contribute to future growth [20]. Conclusion - Yipinhong's AR882 is positioned to fill a significant gap in the gout treatment market, with promising clinical data and a strong development pipeline. The company's strategic initiatives and market potential suggest a positive outlook for future growth and profitability [2][19].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Viewpoints - The report highlights that the demand for hepatitis B cure remains a blue ocean, with CpAMs and small nucleic acid drugs expected to lead the way in achieving functional cures. The large base of hepatitis B infections in China and the limitations of existing therapies create a pressing need for effective treatments [4][15] - The implementation of the "Childcare Subsidy System" is expected to enhance the willingness of families to have children, positively impacting related sectors such as pediatric medicine, medical equipment, and maternal health services [6][21][23] - The pharmaceutical sector saw an overall increase of 2.95% this week, outperforming the CSI 300 index by 4.70 percentage points, with the chemical preparation sector showing the highest growth at 5.48% [25][26] Summary by Sections 1. Hepatitis B Treatment Opportunities - The report emphasizes the significant unmet need for hepatitis B cures in China, with approximately 56 million chronic carriers and a high percentage at risk of severe liver disease [15] - Current approved treatments are limited, with nucleos(t)ide analogs (NAs) and pegylated interferon-α showing inadequate rates of functional cure [15][16] - New drug classes, including CpAMs and small nucleic acids, are in advanced clinical stages, with companies like GSK and AHB-137 leading the way [17][18] 2. Childcare Subsidy System - The newly announced childcare subsidy will provide annual financial support of 3,600 yuan per child under three years old, starting from January 1, 2025 [21][22] - This initiative is expected to boost sectors related to child healthcare and maternal services, enhancing market opportunities for companies in these fields [23][24] 3. Weekly Performance of Pharmaceutical Sector - The pharmaceutical sector's performance this week was marked by a 2.95% increase, with the chemical preparation sector leading at 5.48% [25][26] - The report notes a significant divergence in performance among sub-sectors, with medical devices experiencing a decline of 1.43% [26][32] 4. Beneficiary Stocks - The report identifies several beneficiary stocks across various segments, including innovative drugs (e.g., Innovent Biologics, BeiGene), traditional Chinese medicine (e.g., Jiuzhitang), and medical devices (e.g., Mindray Medical) [8][9][33][40] 5. Market Outlook - The report suggests a positive outlook for innovative drugs driven by overseas expansion and supportive policy developments, with a focus on companies with strong clinical data and market potential [31] - The medical device sector is expected to benefit from upcoming procurement policies and a recovery in demand, particularly for high-end equipment [32][33]

Investment Rating - The report initiates coverage with a "Buy" rating for the company, considering its supply chain advantages, self-operated brand strengths, and the ability to continuously attract third-party merchants and expand O2O services, which are expected to drive steady growth in performance [6][7]. Core Insights - The company has transitioned from a pharmaceutical e-commerce platform to a comprehensive healthcare service provider, offering health product sales, medical services, and smart healthcare solutions, thereby achieving an online closed loop of medical services [14][17]. - The company's self-operated business is the core driver of its performance, with a significant revenue contribution from pharmaceutical and health product sales, which accounted for 84% of total revenue in 2024, growing by 6.9% year-on-year [6][17]. - The online healthcare market is expected to see accelerated penetration, particularly in non-pharmaceutical categories like nutritional supplements and home medical devices, while the pharmaceutical market's online penetration is anticipated to increase due to changing consumer behaviors and regulatory support [6][39]. Financial Data and Profit Forecast - The company forecasts revenues of 63.65 billion, 69.65 billion, and 76.55 billion CNY for 2025, 2026, and 2027 respectively, with net profits of 4.52 billion, 5.04 billion, and 5.79 billion CNY for the same years [6][7]. - The projected earnings per share (EPS) are expected to be 1.41, 1.58, and 1.81 CNY for 2025, 2026, and 2027 respectively, with a net asset return rate gradually increasing to 8.21% by 2027 [6][7]. Market Dynamics - The competitive landscape in the online healthcare sector is expected to stabilize by 2025, with the company leveraging its supply chain, service ecosystem, and AI capabilities to create competitive barriers [6][44]. - The report highlights that the online healthcare service market is still in its early stages, with significant growth potential driven by increased health awareness and the demand for personalized healthcare solutions [41][44]. Key Assumptions - The company anticipates continued growth in pharmaceutical and health product sales through deep collaboration with brand partners, supported by its supply chain advantages [8]. - The platform and advertising services are expected to grow rapidly, with revenue projections of 10.92 billion, 12.38 billion, and 14.04 billion CNY for 2025, 2026, and 2027 respectively [8].

Core Viewpoint - The article discusses the potential second listing of Mindray Medical in Hong Kong, aiming to raise at least $1 billion, amidst a challenging performance period for the company due to industry adjustments and increased competition [1][8]. Group 1: Company Overview - Mindray Medical, founded in 1991 by Li Xiting, initially survived by importing medical devices but shifted to self-development due to high foreign prices and domestic resource shortages [3]. - The company launched its first self-developed multi-parameter monitor in 1993, supported by a government loan [3][4]. - Mindray Medical became one of the first companies in China to attract venture capital in 1995, leading to the development of several key products [4]. Group 2: Financial Performance - In 2024, Mindray Medical's revenue growth is expected to slow significantly, with a projected net profit increase of only 0.74% compared to previous years [1][8]. - The company reported a decline in revenue and net profit in Q1 2025, with revenue down 12.12% and net profit down 16.81% year-on-year [9]. - The life information and support business, which includes core devices like monitors and anesthesia machines, saw an 11.11% revenue decline [8]. Group 3: Strategic Goals - Li Xiting has set an ambitious goal for Mindray Medical to become a top 10 global medical device company by 2030 [1][11]. - The company is focusing on "digital intelligence" and "internationalization" as key strategies to achieve this goal, including the integration of AI into its product lines [11][12]. - Mindray Medical aims for overseas business to account for over 70% of its revenue in the future [12]. Group 4: Market Position and Expansion - Mindray Medical's overseas revenue reached 16.4 billion yuan in 2024, accounting for 44% of total revenue, reflecting its successful international expansion [4][6]. - The company has completed 14 acquisitions from 2011 to 2024, significantly increasing its revenue scale from $881 million to $367 billion [6]. - Mindray Medical is currently ranked 25th in the global medical device company list, with a target to enhance its market share in developing countries [13].

Group 1 - The overall ranking of the fund social media index remains stable, with Baoying Fund replacing Nuoan Fund in the top 19 list [2] - The top content on Douyin focuses on financial interpretations, with Wanjia Fund's analysis of "merger and acquisition policy relaxation" receiving over 30,000 likes [2] - Huaxia Fund and E Fund both emphasize the impact of "interest rate cuts" on investments, resonating with the public's financial concerns, each garnering over 10,000 likes [2] Group 2 - Multiple brand IP programs are featured in the video account rankings, indicating that IP-based operations are a core strategy for content differentiation [3] - The program "Planting Time" by Zhongou Fund uses dance to illustrate investment philosophy, achieving over 8,000 likes [3] - The "Curiosity Camp" series by Harvest Fund provides in-depth analysis of AI in healthcare, engaging users with relatable scenarios and generating high engagement [3] Group 3 - The high-traffic content on the Zhaocai account primarily consists of lightweight graphic articles focused on investment strategies and product education [4] - Live broadcasts on the Wealth account mainly feature product promotions and strategy meetings [5] - The public account strategy combines red envelope benefits with investor education and product promotion [6]

本期为基金社交媒体指数（2025年6月）。 本期为基金社交媒体指数（2025年6月）。 本期总榜保持稳定，仅宝盈基金（TOP19）替换诺安基金（5月TOP19）进入榜单。 本期基金抖音高赞榜上榜作品以财经解读为主。万家基金解读"并购重组政策松绑"热点，用"资本相亲大会"比喻降低用户理解门槛，收获3万+点赞。华夏基 金、易方达基金不约而同聚焦"降准降息"政策对投资带来的影响，关联普通人钱袋子，均收获了上万点赞，显示用户对宏观事件如何影响投资的强关注。嘉 实基金、华富基金、国泰基金则挖掘前瞻性产业趋势，用通俗语言分析高成长性赛道的未来机会。此外，榜首作品华安基金《人生没有白走的路，但走自己 选的路时，每一步都带风》上演励志温情小剧场，精准演绎了毕业季年轻人对未来选择的犹豫，是听父母的决定还是坚持自我，强烈的情绪共鸣引发了10万 用户点赞。 视频号方面，本期多个品牌IP栏目上榜（如中欧基金「种时光的人」、富国合唱团、嘉实基金《好奇心营地》等），IP化运营已成为视频号内容突围的核心 策略。中欧基金「种时光的人」上榜作品用舞蹈艺术《只此青绿》诠释投资哲学，将"长期主义"具象化为文化符号，深度叙事收获用户8千+点赞。富国 ...

图丨 Ambience Healthcare（来源：Ambience Healthcare） 自 2020 年由两位美国麻省理工学院校友 Mike Ng 和 Nikhil Buduma 共同创立以来，这家总部位于美国旧金山的公司始终致力于解决一个长期困扰全球医 疗系统的核心痛点：繁重的文书工作。据统计，超过九成的医生表示他们经常感到职业倦怠，而处理大量的文档和行政任务是导致这一问题的主要原因。 医疗专业人员，包括医生、护士和各类专科医师，每天都需要花费大量时间在电子健康记录（EHR，Electronic Health Records）的录入、图表摘要的准 备、临床文档的生成以及计费编码的转换等非诊疗性工作上，这不仅严重挤占了他们与患者直接交流的时间，也带来了巨大的精神压力和运营成本。 Ambience Healthcare 的诞生，正是为了利用 AI 技术，将临床医生从这些重复、琐碎的行政任务中解放出来。 全球 AI 医疗市场正经历前所未有的快速增长。根据最新的市场研究预测，该市场规模预计将从 2024 年的 26.69 亿美元飙升至 2030 年的 188.38 亿美元， 年复合增长率高达 38.62%。在 ...